One case of anaphylaxis due to recurrent cervical cancer treated with candonilimab
10.12173/j.issn.1005-0698.202410068
- VernacularTitle:卡度尼利单抗治疗复发性宫颈癌致过敏性休克1例
- Author:
Xiali ZHANG
1
;
Li MI
;
Jingchao LI
Author Information
1. 武警上海市总队医院药剂科(上海 201103)
- Publication Type:Journal Article
- Keywords:
Candonilimab;
Recurrent cervical cancer;
Anaphylaxis;
Adverse drug reactions
- From:
Chinese Journal of Pharmacoepidemiology
2025;34(5):600-604
- CountryChina
- Language:Chinese
-
Abstract:
A 49-year-old female patient with recurrent cervical cancer was treated with injectable paclitaxel(albumin-bound)(400 mg,ivd,d1)+injectable cisplatin 100 mg,intraperitoneal instillation,d1+candonilimab injection(375 mg,ivd,d7).During the 2nd cycle of treatment,when the intravenous infusion of candonilimab was about 8 minutes,the patient suddenly had symptoms such as flushing,shortness of breath,cardiac discomfort,blurred consciousness with profuse sweating,etc.The candonilimab was immediately suspended,and after resuscitation,the patient's vital signs stabilised,and the treatment of the primary disease with candonilimab was terminated.According to the principle of correlation evaluation in Adverse Drug Reaction Reporting and Monitoring Workbook,the correlation between anaphylaxis and candonilimab was evaluated to be"very likely",and the common types of adverse reactions to candonilimab,the mechanism of anaphylaxis and pretreatment measures were also reviewed,with a view to providing referable opinions on the whole course of management of candonilimab and promoting the rational use of the drug in clinical safety.
